14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Monday, 6th May 2024 MDGL stock ended at $235.57. This is 2.49% more than the trading day before Friday, 3rd May 2024. During the day the stock fluctuated 3.58% from a day low at $228.48 to a day high of $236.65.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Madrigal Pharmaceuticals, Inc. prices

Date Open High Low Close Volume
Feb 23, 2024 $249.36 $249.98 $235.10 $236.54 466 166
Feb 22, 2024 $230.47 $252.96 $230.47 $248.53 587 594
Feb 21, 2024 $228.97 $235.02 $225.02 $228.24 416 743
Feb 20, 2024 $232.85 $238.55 $227.00 $229.71 326 822
Feb 16, 2024 $219.35 $241.87 $219.35 $233.13 599 433
Feb 15, 2024 $217.54 $223.40 $214.00 $222.22 379 977
Feb 14, 2024 $208.85 $225.00 $208.09 $217.98 510 527
Feb 13, 2024 $208.68 $214.63 $203.53 $204.80 646 126
Feb 12, 2024 $192.90 $218.47 $191.30 $216.33 947 695
Feb 09, 2024 $172.61 $189.98 $168.25 $189.88 873 336
Feb 08, 2024 $189.30 $191.74 $169.05 $171.37 1 386 307
Feb 07, 2024 $205.10 $207.38 $180.00 $188.54 1 022 210
Feb 06, 2024 $189.70 $203.65 $171.35 $201.44 2 867 353
Feb 05, 2024 $217.51 $227.16 $213.82 $227.05 392 803
Feb 02, 2024 $219.15 $222.50 $216.00 $220.28 161 857
Feb 01, 2024 $218.87 $223.65 $215.16 $222.23 258 976
Jan 31, 2024 $222.44 $224.99 $216.66 $216.71 235 773
Jan 30, 2024 $225.17 $225.99 $217.36 $221.07 205 956
Jan 29, 2024 $226.16 $228.23 $220.21 $226.99 221 410
Jan 26, 2024 $230.89 $231.96 $224.15 $225.97 234 766
Jan 25, 2024 $226.14 $239.21 $225.39 $230.17 241 135
Jan 24, 2024 $233.44 $233.44 $222.20 $222.91 257 679
Jan 23, 2024 $236.18 $237.00 $223.55 $229.00 233 848
Jan 22, 2024 $226.00 $235.17 $216.35 $233.18 324 401
Jan 19, 2024 $224.16 $230.88 $220.01 $226.48 273 177
Click to get the best stock tips daily for free!

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,... MDGL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT